| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049238988 |
| P356 | DOI | 10.1038/LEU.2017.10 |
| P698 | PubMed publication ID | 28074072 |
| P50 | author | Steven Goossens | Q38545837 |
| Geert Berx | Q42648738 | ||
| Beat C Bornhauser | Q58230167 | ||
| Jean-Pierre Bourquin | Q58316774 | ||
| Sofie Peirs | Q89499703 | ||
| P2093 | author name string | B Poppe | |
| T Pieters | |||
| P Van Vlierberghe | |||
| N Vandamme | |||
| B Lintermans | |||
| F Matthijssens | |||
| M P Dobay | |||
| V Frismantas | |||
| W Van Loocke | |||
| P2860 | cites work | The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability | Q24296476 |
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 | ||
| The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics | Q27010154 | ||
| The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease | Q27015587 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Gene Expression Omnibus: NCBI gene expression and hybridization array data repository | Q27860523 | ||
| Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination | Q28118450 | ||
| Targeting bromodomains: epigenetic readers of lysine acetylation | Q28238635 | ||
| Super-enhancers in the control of cell identity and disease | Q28661442 | ||
| Selective inhibition of tumor oncogenes by disruption of super-enhancers | Q29617301 | ||
| Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. | Q33412553 | ||
| MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 | ||
| Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | Q33431391 | ||
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 | ||
| BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines | Q33578868 | ||
| Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance | Q33755338 | ||
| Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group | Q33800438 | ||
| BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma | Q33853887 | ||
| A public genome-scale lentiviral expression library of human ORFs | Q33943308 | ||
| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study | Q34046624 | ||
| Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199 | Q34135298 | ||
| A revised definition for cure of childhood acute lymphoblastic leukemia. | Q34429332 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo | Q34621429 | ||
| Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma | Q35087551 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells | Q36057611 | ||
| Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib | Q36091288 | ||
| Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options | Q36154689 | ||
| Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? | Q36163029 | ||
| Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics | Q36231912 | ||
| Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) | Q36349985 | ||
| MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma | Q36546300 | ||
| Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells | Q36642752 | ||
| BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction | Q37523017 | ||
| c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells | Q37585215 | ||
| Adult acute lymphoblastic leukemia: concepts and strategies | Q37681450 | ||
| Modern therapy of acute lymphoblastic leukemia | Q37827276 | ||
| Relapsed childhood acute lymphoblastic leukaemia | Q38103645 | ||
| ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development | Q38640917 | ||
| BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. | Q38779981 | ||
| Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia | Q38860425 | ||
| Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas | Q38881837 | ||
| Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma | Q38896657 | ||
| ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells | Q38942453 | ||
| ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia | Q38949201 | ||
| Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. | Q38999126 | ||
| Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. | Q38999783 | ||
| Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression | Q39924163 | ||
| Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition | Q42702750 | ||
| Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL | Q42705204 | ||
| Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia. | Q49050005 | ||
| Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | Q55070853 | ||
| Acute lymphoblastic leukemia | Q79891876 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 2037-2047 | |
| P577 | publication date | 2017-01-11 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia | |
| P478 | volume | 31 |
| Q39207675 | A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers |
| Q42378528 | BET inhibitors as novel therapeutic agents in breast cancer. |
| Q64272902 | Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy |
| Q91623240 | Bromodomains: a new target class for drug development |
| Q64061318 | Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy |
| Q91845925 | Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia |
| Q50863471 | MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy. |
| Q90950048 | PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis |
| Q38637652 | Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies |
| Q64096005 | Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity |
| Q90350507 | Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma |
| Q65000502 | The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. |
| Q58702132 | Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant |
Search more.